{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:09:00Z","timestamp":1771927740161,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Epidermal growth factor receptor (\n                    <jats:italic>EGFR<\/jats:italic>\n                    ) exon 19 deletion (Ex19del) is one of the most prevalent sensitizing mutations in non-small cell lung cancer (NSCLC), particularly in Asian populations. However, management after progression or suboptimal response is unclear. We describe two patients with advanced lung adenocarcinoma harboring\n                    <jats:italic>EGFR<\/jats:italic>\n                    Ex19del who received furmonertinib plus pemetrexed. Case 1 achieved partial response (PR) with substantial tumor shrinkage and a marked decline in carcinoembryonic antigen (CEA) after six cycles; disease remained stable over 19 months of follow-up. Case 2 had suboptimal benefit from first-line osimertinib but attained PR with resolution of pleural effusion after switching to the combination; subsequent computed tomography (CT) confirmed stable disease (SD). Both patients tolerated treatment without severe treatment-related adverse events. These observations suggest that furmonertinib plus pemetrexed may have antitumor activity and acceptable tolerability in\n                    <jats:italic>EGFR<\/jats:italic>\n                    Ex19del lung adenocarcinoma, and may inform personalized approaches following resistance to first-line therapy in\n                    <jats:italic>EGFR<\/jats:italic>\n                    -sensitizing NSCLC.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1709552","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T05:23:22Z","timestamp":1769664202000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Furmonertinib plus pemetrexed in the treatment of EGFR exon 19 deletion lung adenocarcinoma: two case reports"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuan","family":"Zhang","sequence":"first","affiliation":[{"name":"The First School of Clinical Medical, Gansu University of Chinese Medicine","place":["Lanzhou, Gansu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duofang","family":"Wang","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medical, Gansu University of Chinese Medicine","place":["Lanzhou, Gansu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaxiu","family":"Ma","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medical, Gansu University of Chinese Medicine","place":["Lanzhou, Gansu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Wang","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medical, Gansu University of Chinese Medicine","place":["Lanzhou, Gansu, China"]},{"name":"Department of Respiratory and Critical Care Medicine, Gansu Provincial Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: A meta-analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol Diagn Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"New Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.1438","article-title":"EGFR-TKI combined with pemetrexed versus EGFR-TKI monotherapy in advanced EGFR-mutated NSCLC: A prospective, randomized, exploratory study","volume":"55","author":"Gu","year":"2023","journal-title":"Cancer Res Treat"},{"key":"B8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12916-024-03389-w","article-title":"Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer","volume":"22","author":"Han","year":"2024","journal-title":"BMC Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"New Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1332057","article-title":"Targeting HER3 to overcome EGFR TKI resistance in NSCLC","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B15","doi-asserted-by":"publisher","first-page":"101260","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"53","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"101260","DOI":"10.1016\/j.lanwpc.2024.101260","article-title":"Consensus on the lung cancer management after third-generation EGFR-TKI resistance","volume":"53","author":"Zhou","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"B17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000362819","article-title":"Challenges in the management of EGFR-mutated non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors","volume":"87","author":"Kuiper","year":"2014","journal-title":"Oncology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/lctt.S385437","article-title":"Spotlight on furmonertinib (Alflutinib, AST2818). The swiss army knife (del19, L858R, T790M, exon 20 insertions, \u201cuncommon-G719X, S768I, L861Q\u201d) among the third-generation EGFR TKIs","volume":"13","author":"Zhang","year":"2022","journal-title":"Lung Cancer (Auckl)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41401-021-00667-8","article-title":"Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans","volume":"43","author":"Meng","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1357913","article-title":"Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI","volume":"15","author":"Ding","year":"2024","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107346","article-title":"Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study","volume":"184","author":"Qi","year":"2023","journal-title":"Lung Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx704","article-title":"Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients","volume":"29","author":"Remon","year":"2018","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20311","article-title":"The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer","volume":"8","author":"Zhong","year":"2017","journal-title":"Oncotarget"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510308","article-title":"Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC","volume":"394","author":"J\u00e4nne","year":"2026","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.598265","article-title":"First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutation: A systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Wu","year":"2021","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-24-1515","article-title":"Eradicating drug-tolerant persister cells in EGFR-mutated non-small cell lung cancer by targeting TROP2 with CAR-T cellular therapy","volume":"15","author":"Baldacci","year":"2025","journal-title":"Cancer Discov"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.3390\/cells10071590","article-title":"Drug tolerance to EGFR tyrosine kinase inhibitors in lung cancers with EGFR mutations","volume":"10","author":"Suda","year":"2021","journal-title":"Cells"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.70068","article-title":"CD24 is a promising immunotherapeutic target for enhancing efficacy of third-generation EGFR-TKIs on EGFR-mutated lung cancer","volume":"45","author":"Liang","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e142843","DOI":"10.1172\/jci.insight.142843","article-title":"Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC","volume":"7","author":"Tu","year":"2022","journal-title":"JCI Insight"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-20-0071","article-title":"Amivantamab (JNJ-61186372), an fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","article-title":"Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications","volume":"24","author":"Cho","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.12.029","article-title":"Amivantamab plus lazertinib in patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy: results from CHRYSALIS-2 cohort A","volume":"20","author":"Besse","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.3390\/cancers17111750","article-title":"Efficacy and safety of TROP-2-targeting antibody-drug conjugate treatment in previously treated patients with advanced non-small cell lung cancer: A systematic review and pooled analysis of reconstructed patient data","volume":"17","author":"Stumpo","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"10048","DOI":"10.1038\/s41467-025-66376-6","article-title":"Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-22-0111","article-title":"AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer","volume":"12","author":"Noronha","year":"2022","journal-title":"Cancer Discov"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15674","article-title":"Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer","volume":"114","author":"Takahashi","year":"2023","journal-title":"Cancer Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.ccell.2021.07.006","article-title":"Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis","volume":"39","author":"Tanaka","year":"2021","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1709552\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:15:34Z","timestamp":1771924534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1709552\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":41,"alternative-id":["10.3389\/fonc.2026.1709552"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1709552","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"article-number":"1709552"}}